GPRASP1 Antibody

What is GPRASP1 and why is it significant for research?

GPRASP1, also known as GASP, GASP1, or KIAA0443, belongs to the GPRASP protein family and plays a crucial role in modulating lysosomal sorting and functional down-regulation of G protein-coupled receptors (GPCRs) . With a molecular weight of approximately 157 kDa, GPRASP1 contains short repeated sequences called GASP motifs that are critically involved in protein-protein interactions with GPCRs . The protein is primarily responsible for targeting receptors for degradation in lysosomes, making it an essential regulator of GPCR turnover and signaling dynamics . Recent research has identified GPRASP1 as a potential anti-oncogene in head and neck cancer and a critical regulator of hematopoietic stem cell function, highlighting its broader physiological significance beyond receptor trafficking .

What applications are GPRASP1 antibodies validated for?

GPRASP1 antibodies have been validated for multiple experimental applications:

These antibodies have been successfully used in published research for detecting endogenous GPRASP1 expression, analyzing protein-protein interactions, and investigating subcellular localization . When selecting an antibody, researchers should consider their specific application requirements and validate the antibody in their experimental system.

How should researchers optimize antigen retrieval for GPRASP1 immunohistochemistry?

For optimal GPRASP1 detection in immunohistochemistry applications, antigen retrieval methodology is critical. The recommended primary approach is to use TE buffer at pH 9.0 for antigen retrieval . Alternatively, citrate buffer at pH 6.0 may be used if the primary method does not yield satisfactory results . The optimal retrieval method may vary depending on tissue type, fixation protocol, and the specific antibody being used.

For human brain tissue, which shows strong GPRASP1 expression and serves as an excellent positive control, TE buffer at pH 9.0 typically yields the best results . After antigen retrieval, researchers should implement a thorough blocking step to minimize background staining, particularly in tissues with high endogenous peroxidase activity. Antibody dilutions in the range of 1:20-1:200 are recommended for IHC applications, but optimal concentrations should be determined empirically for each tissue type and experimental system .

What are the critical controls needed when using GPRASP1 antibodies?

Implementing proper controls is essential for accurate interpretation of results when using GPRASP1 antibodies:

Positive Controls:

• Human brain tissue and mouse brain tissue show strong GPRASP1 expression

• HeLa cells and HepG2 cells are suitable positive controls for cell-based experiments

Negative Controls:

• Omission of primary antibody to assess secondary antibody specificity

• Peptide competition assays using the immunizing peptide to verify antibody specificity

• GPRASP1 knockout or knockdown samples (when available)

• For anti-GASP motif antibodies specifically, mutants of GPRASP proteins in which the conserved hydrophobic core of the GASP motifs is mutated should not be detected, serving as excellent negative controls

Validation Across Methods:
Confirmation of results using multiple techniques (WB, IHC, IF) provides more robust validation. For instance, if GPRASP1 is detected in a tissue section by IHC, verification by Western blot showing a band at the expected 157 kDa molecular weight strengthens confidence in the finding .

How can researchers effectively troubleshoot non-specific binding with GPRASP1 antibodies?

Non-specific binding is a common challenge when working with GPRASP1 antibodies. Several methodological approaches can address this issue:

• Antibody Titration: The optimal antibody concentration varies by application and sample type. It is strongly recommended to titrate the antibody in each testing system to determine the ideal concentration that maximizes specific signal while minimizing background .

• Enhanced Blocking Protocols: For tissues or cells with high background:

  • Extend blocking time to 1-2 hours at room temperature

  • Use 5-10% normal serum from the species of the secondary antibody

  • Add 0.1-0.3% Triton X-100 to blocking solution for balanced permeabilization

• Buffer Optimization: For Western blot applications, increasing the salt concentration in wash buffers (up to 500 mM NaCl) can reduce non-specific ionic interactions.

• Sample-Specific Considerations: When working with brain tissue, where GPRASP1 is highly expressed, more stringent washing and higher antibody dilutions may be required compared to tissues with lower expression levels .

• Cross-reactivity Assessment: Some GPRASP1 antibodies may cross-react with other GPRASP family members due to sequence homology. Whenever possible, validate findings using antibodies targeting different epitopes .

What are the optimal storage conditions for maintaining GPRASP1 antibody activity?

Proper storage is crucial for preserving GPRASP1 antibody activity and ensuring reproducible results:

How can anti-GASP motif antibodies be utilized to study GPCR trafficking mechanisms?

Anti-GASP motif antibodies represent sophisticated tools for investigating GPCR trafficking and degradation pathways:

Research has characterized anti-GASP motif antibodies that can detect both GPRASP1 and GPRASP2 in Western blot, immunoprecipitation, and immunofluorescence experiments . These antibodies specifically recognize the GASP motifs, which function as multivalent epitopes critical for GPCR interactions.

Experimental Applications:

• Interaction Disruption Studies: Anti-GASP motif antibodies can efficiently inhibit the interaction between purified ADRB2 receptor and the central domain of GPRASP1, as demonstrated using Amplified Luminescent Proximity Homogeneous AlphaScreen® assay . This provides a powerful tool for:

  • Investigating the consequences of disrupting specific GPRASP1-GPCR interactions

  • Identifying which GPCRs depend on GASP motif interactions for lysosomal targeting

  • Studying the kinetics of receptor downregulation when GASP interactions are blocked

• Real-time Trafficking Analysis: By pre-treating cells with anti-GASP motif antibodies and then tracking fluorescently-tagged GPCRs, researchers can visualize changes in receptor internalization, recycling, and degradation pathways.

• Receptor Fate Manipulation: Since GPRASP1 targets receptors for degradation in lysosomes, blocking this interaction with anti-GASP motif antibodies could potentially extend receptor half-life and enhance signaling, offering insights into the physiological consequences of altered GPCR turnover .

What role does GPRASP1 play in cancer, and how can antibodies help investigate this function?

Recent research has identified GPRASP1 as a candidate anti-oncogene with significant implications for cancer progression and treatment response, particularly in head and neck cancer (HNC) :

Expression and Clinical Correlations:

• GPRASP1 is significantly downregulated in HNC compared to normal tissues

• Lower GPRASP1 expression correlates with adverse clinical features:

  • Perineural invasion

  • Higher histologic grade

  • Advanced T stage and TNM stage

• GPRASP1 serves as an independent predictor of favorable prognosis (HR: 0.42, 95% CI 0.20–0.91, p = 0.028)

Immune Microenvironment Associations:
High GPRASP1 expression significantly correlates with:

• Enhanced immune cell infiltration (CD8+ T cells, tumor-infiltrating lymphocytes)

• Upregulation of immune-related pathways (cytolytic activity, checkpoint pathways)

• Expression of immune checkpoint inhibitors (CTLA4, LAG3, PDCD1, TIGIT)

Research Applications of GPRASP1 Antibodies in Cancer:

• Prognostic Biomarker Development: GPRASP1 antibodies can be used for immunohistochemical analysis of tumor specimens to assess expression levels and correlate with clinical outcomes .

• Mechanistic Studies: Combining GPRASP1 antibodies with other markers can help elucidate how GPRASP1 influences the tumor immune microenvironment:

  • Co-staining with immune cell markers to quantify infiltration

  • Evaluating GPCR expression and localization in GPRASP1-high versus GPRASP1-low tumors

  • Investigating downstream signaling pathways affected by GPRASP1 expression

• Therapeutic Response Prediction: Given the correlation between GPRASP1 expression and immune checkpoint molecules, antibody-based detection might help predict response to immunotherapies .

How do GPRASP proteins regulate hematopoietic stem cell function, and what antibody-based approaches can investigate this relationship?

Research has identified GPRASP family members as critical negative regulators of hematopoietic stem cell (HSC) function, with significant implications for hematopoietic stem cell transplantation :

Regulatory Mechanism:

GPRASP1 and GPRASP2 promote the degradation of CXCR4, a master regulator of HSC function during transplantation . When GPRASP1 or GPRASP2 is silenced or knocked down:

• CXCR4 accumulates in hematopoietic stem and progenitor cells (HSPCs)

• This accumulation leads to increased survival, enhanced quiescence, improved migration, better niche retention, and superior hematopoietic repopulating activity

• These effects boost HSPC function following transplantation

Antibody-Based Investigative Approaches:

• Expression Analysis: GPRASP1 antibodies can be used to quantify expression levels across different hematopoietic stem and progenitor cell populations:

  • Long-term HSCs (LT-HSCs)

  • Short-term HSCs (ST-HSCs)

  • Multipotent progenitors (MPPs)

  • Lineage-committed progenitors

• CXCR4 Trafficking Studies: Combining GPRASP1 antibodies with CXCR4 antibodies in immunofluorescence experiments can reveal:

  • Co-localization patterns in different cellular compartments

  • Changes in receptor distribution following cytokine stimulation

  • Alterations in trafficking dynamics when GPRASP levels are manipulated

• Degradation Pathway Analysis: GPRASP1 antibodies can help track the association of CXCR4 with lysosomal compartments, providing insights into the degradation pathway and its regulation .

• In vivo Transplantation Studies: Manipulating GPRASP/CXCR4 interactions could potentially enhance hematopoietic stem cell transplantation efficiency, with GPRASP1 antibodies serving as valuable tools to verify expression levels in transplanted cells .

How can researchers address the challenge of functional redundancy when studying GPRASP family members?

The GPRASP family consists of multiple members with potential functional redundancy, complicating the interpretation of single-gene knockdown or knockout studies . Researchers have observed that in GPRASP1-/- or GPRASP2-/- models, other family members (like Bhlhb9) may be upregulated to compensate for the loss .

Methodological Approaches to Address Redundancy:

• Combined Targeting Strategies:

  • Simultaneous knockdown of multiple GPRASP family members using combinatorial shRNA approaches

  • CRISPR/Cas9 targeting of conserved domains across family members

  • Pharmacological inhibition of shared downstream pathways

• Domain-Specific Antibodies:

  • Anti-GASP motif antibodies that recognize conserved epitopes across family members can help study collective family function

  • These antibodies can neutralize the interaction of multiple GPRASP proteins with GPCRs simultaneously

• Differential Expression Analysis:

  • Quantitative comparison of expression levels across family members in a given tissue or cell type

  • Identification of the predominant family member in specific cellular contexts

• Rescue Experiments:

  • Testing whether expression of one family member can rescue phenotypes caused by deficiency of another

  • Constructing chimeric proteins to identify which domains are functionally interchangeable

• Systems Biology Approaches:

  • Network analysis to identify unique and overlapping interaction partners

  • Computational prediction of functional redundancy based on protein structure and domain organization

How might GPRASP1 antibodies contribute to cancer immunotherapy research?

Given GPRASP1's emerging role as a potential anti-oncogene with significant correlations to immune microenvironment features, GPRASP1 antibodies could make substantial contributions to cancer immunotherapy research :

Biomarker Development:

• GPRASP1 antibodies could be used to develop immunohistochemical assays for predicting response to immunotherapy

• Expression patterns might help stratify patients for clinical trials of immune checkpoint inhibitors

Mechanistic Investigations:

• Dual-staining with GPRASP1 and immune cell markers could reveal spatial relationships between GPRASP1 expression and immune infiltration

• Time-course studies following immunotherapy might reveal whether GPRASP1 expression changes in response to treatment

Novel Therapeutic Approaches:

• If GPRASP1 regulates immune-related GPCRs, manipulating this interaction could potentially enhance anti-tumor immune responses

• Anti-GASP motif antibodies might be developed as therapeutic agents to modulate GPCR trafficking in cancer cells

Personalized Medicine Applications:

• Combined analysis of GPRASP1 expression with other biomarkers could yield more robust predictive algorithms for immunotherapy response

• Longitudinal monitoring of GPRASP1 levels might help track treatment efficacy or emergence of resistance mechanisms

What emerging technologies could enhance GPRASP1 antibody-based research?

Several cutting-edge technologies hold promise for advancing GPRASP1 antibody-based research:

• Proximity Ligation Assays (PLA):

  • Enables visualization of protein-protein interactions in situ with high sensitivity

  • Could reveal GPRASP1 interactions with specific GPCRs in native cellular contexts

  • May help identify novel interaction partners in different cell types or disease states

• Mass Cytometry (CyTOF):

  • Allows simultaneous detection of dozens of protein markers on single cells

  • Could help characterize GPRASP1 expression across heterogeneous cell populations

  • May reveal correlations between GPRASP1 levels and various cellular phenotypes

• Spatial Transcriptomics and Proteomics:

  • Combines tissue morphology with molecular profiling at near-cellular resolution

  • Could map GPRASP1 protein expression in relation to mRNA levels and spatial context

  • May identify tissue microenvironments where GPRASP1 function is particularly important

• Nanobody Development:

  • Smaller antibody fragments with enhanced tissue penetration

  • Could improve in vivo imaging of GPRASP1 expression

  • May enable more effective manipulation of GPRASP1 function in cellular compartments

• Antibody-Drug Conjugates (ADCs):

  • Could target therapeutic payloads to cells with aberrant GPRASP1 expression

  • Might be particularly relevant in cancers where GPRASP1 expression is altered

How can researchers verify GPRASP1 antibody specificity when studying complex tissues?

Ensuring antibody specificity is particularly challenging when studying GPRASP1 in complex tissues due to potential cross-reactivity with other GPRASP family members and the presence of splice variants. Researchers should implement a multi-faceted validation strategy:

• Genetic Control Validation:

  • Use GPRASP1 knockout tissues or cells (when available)

  • Employ siRNA/shRNA knockdown samples as negative controls

  • Compare staining patterns with known expression data from transcriptomic studies

• Epitope Mapping:

  • Select antibodies targeting unique regions of GPRASP1 not conserved in other family members

  • Use epitope-tagged GPRASP1 constructs to confirm antibody recognition

  • Consider generating custom antibodies against highly specific regions

• Cross-Platform Validation:

  • Confirm IHC/IF findings with Western blot showing a band at the expected 157 kDa

  • Correlate protein detection with mRNA expression data

  • Use multiple antibodies targeting different epitopes to verify consistent patterns

• Absorption Controls:

  • Pre-absorb antibodies with recombinant GPRASP1 protein or immunizing peptide

  • Include related family members in absorption tests to assess cross-reactivity

  • Implement competitive binding assays to demonstrate specificity

• Species-Specific Considerations:

  • Verify antibody reactivity across species of interest (human vs. mouse reactivity is documented for several antibodies)

  • Consider species-specific antibodies for comparative studies

What standardization approaches should be implemented for GPRASP1 antibody-based research?

To enhance reproducibility and facilitate comparison across studies, researchers should adopt standardized approaches for GPRASP1 antibody-based research:

• Reporting Standards:

  • Document complete antibody information: manufacturer, catalog number, lot number, RRID

  • Specify detailed experimental conditions: dilutions, incubation times, temperatures, buffer compositions

  • Include all validation steps performed and their results

• Quantification Methods:

  • Adopt standardized scoring systems for IHC (e.g., H-score, Allred score)

  • Use digital image analysis with consistent thresholding parameters

  • Report both intensity and distribution of staining

• Reference Materials:

  • Establish common positive and negative control samples

  • Create standard curves using recombinant proteins for quantitative applications

  • Consider tissue microarrays with graduated expression levels for calibration

• Interlaboratory Validation:

  • Participate in ring trials to assess reproducibility across laboratories

  • Share detailed protocols through repositories like protocols.io

  • Contribute validated antibody data to resources like Antibodypedia

• Data Integration:

  • Correlate antibody-based findings with orthogonal methods (mass spectrometry, RNA-seq)

  • Deposit raw image data in public repositories

  • Link antibody-based studies with existing datasets through consistent metadata

By implementing these standardization approaches, researchers can build a more coherent body of knowledge regarding GPRASP1 function across different biological systems and disease contexts.